Stock 6540 JHL BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News JHL Biotech, Inc.

Equities

6540

KYG7863U1076

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.
CI
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
CI
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma
CI
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer
CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar
CI
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma
CI
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer
CI
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors
CI
JHL Biotech Seeks Financing
CI
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application
CI
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index
CI
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.
CI
JHL Biotech, Inc. announced that it expects to receive $150 million in funding
CI
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis
CI
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers
CI
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials
CI
JHL Doses First Patient In JHL1101 Phase I European Trial
CI
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China
CI
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6540 Stock
  4. News JHL Biotech, Inc.